Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Dave, RV; Elsberger, B; Taxiarchi, VP; Gandhi, A; Kirwan, CC; Kim, B; Camacho, EM; Coles, CE; Copson, E; Courtney, A; Horgan, K; Fairbrother, P; Holcombe, C; Kirkham, JJ; Leff, DR; McIntosh, SA; O’Connell, R; Pardo, R; Potter, S; Rattay, T; Sharma, N; Vidya, R; Cutress, RI

Journal article

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Abstract:: Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb–July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32–81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7–8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months’ treatment duration; median of 4 mm [IQR − 20, 4]. In a small subset of patients ( n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month’s duration of BrET. Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Dave, R. V., Elsberger, B., Taxiarchi, V. P., Gandhi, A., Kirwan, C. C., Kim, B., Camacho, E. M., Coles, C. E., Copson, E., Courtney, A., Horgan, K., Fairbrother, P., Holcombe, C., Kirkham, J. J., Leff, D. R., McIntosh, S. A., O’Connell, R., Pardo, R., Potter, S., … Cutress, R. I. (2023). Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study. Breast Cancer Research and Treatment, 199(2), 265–279.

MLA Style

Dave, RV, et al. “Bridging Pre-Surgical Endocrine Therapy for Breast Cancer during the COVID-19 Pandemic: Outcomes from the B-MaP-C Study.” Breast Cancer Research and Treatment, vol. 199, no. 2, 2023, pp. 265–79.

Chicago Style

Dave, RV, B Elsberger, VP Taxiarchi, et al. 2023. “Bridging Pre-Surgical Endocrine Therapy for Breast Cancer during the COVID-19 Pandemic: Outcomes from the B-MaP-C Study.” Breast Cancer Research and Treatment 199 (2): 265–79.
Print